Pharmaceutical companies are 'stifling innovation' by delaying generic medicines, EC says

摘要

Many pharmaceutical companies appear to be using delaying or blocking tactics to prevent generic companies from marketing medicines, thus stifling innovation, the European Commission says in a preliminary report from its pharmaceutical sector anti-trust inquiry.